Percutaneous cranial nerve dual-mode radiofrequency therapy for peripheral facial paralysis related diseases

A clinical study of percutaneous cranial nerve dual-mode radiofrequency therapy for peripheral facial paralysis related diseases

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100049733

Enrollment

Unknown

Registered

2021-08-08

Start date

2021-08-09

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral sex facial paralysis disease

Interventions

Idiopathic facial paralysis drug treatment group:medical treatement

Idiopathic facial paralysis EMG biofeedback treatment group:Electromyography biofeedback therapy

Idiopathic facial paralysis dual-mode radiofrequency treatment group:Dual mode radiofrequency therapy

Hunter syndrome drug therapy group:medical treatement

Hunter syndrome electromyography biofeedback treatment group:Electromyography biofeedback therapy

Hunter syndrome dual-mode radiofrequency treatment group:Dual mode radiofrequency therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Inclusion criteria for Hunt syndrome: (1) Patients with Hunter syndrome were diagnosed according to UpToDate, Herpes zoster caused by Varicella zoster Virus infection 20190121. (2) Main symptoms: lateral paralysis, earache, ear canal and auricle herpes; (3) After drug treatment >1 week, facial nerve function grade >= II; (4) Treatment >1 week, VAS score >=3; (5) Aged 18 to 80 years; (6) Be able to correctly describe their own wishes, voluntarily fill in the informed consent, and agree to participate in the clinical subjects; 2.Inclusion criteria for idiopathic facial paralysis: (1) Acute onset, usually reaching a peak in about 3 days; (2) Smooth unilateral peripheral facial paralysis, with or without pain behind the ear, prelingual taste loss, hearing allergy, abnormal tear or saliva secretion; (3) Exclude secondary causes.

Exclusion criteria

Exclusion criteria: 1. Patients suffering from stroke within six months; 2. Patients with intracranial tumors; 3. Patients with co-infectious diseases 4. Patients with coagulation dysfunction; 5. Women who are pregnant or breastfeeding, those who are planning to become pregnant during treatment; 6. Mental patients; 7. When the clinical investigator believes that the subjects participating in the clinical research cannot cooperate with the treatment.

Design outcomes

Primary

Measure	Time frame
Visual Analogue Score (VAS Score);facial nerve function score;Pittsburgh Sleep Quality Score;	—

Countries

China

Contacts

Public ContactTao Gaojian

Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School

719478745@qq.com+86 13851824697

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026